Inventors:
Michael M. Lipp - Framingham MA, US
Robert W. Clarke - Medfield MA, US
David L. Hava - Natick MA, US
Richard Batycky - Newton MA, US
John Hanrahan - West Roxbury MA, US
Assignee:
Pulmatrix, Inc. - Lexington MA
International Classification:
A61K 33/42, A61K 33/10, A61K 33/06, A61K 33/00, A61K 33/04, A61K 33/22, A61K 31/19, A61K 31/734, A61K 31/20, A61K 31/191, A61K 31/194, A61K 31/375, A61K 31/192, A61P 31/00, A61K 33/14
US Classification:
424602, 424678, 424687, 424696, 424680, 424717, 424715, 424709, 424606, 424711, 424660, 424600, 514557, 514 54, 514558, 514574, 514474, 514568
Abstract:
The present invention relates to pharmaceutical formulations for treating a respiratory tract infection or a pulmonary disease in an individual, comprising a calcium salt and a sodium salt, wherein the ratio of Cato Na is from about 4:1 (mole:mole) to about 16:1 (mole:mole). The invention also relates to methods of treating (including prophylactically treating) and reducing the spread of a respiratory tract infection, methods of treating (including prophylactically treating) a pulmonary disease or an acute exacerbation of a pulmonary disease, and methods of reducing the spread of an acute exacerbation of a pulmonary disease, comprising administering a pharmaceutical formulation that comprises a calcium salt and a sodium salt.